SRAP SIGNED

Project "SRAP" data sheet

The following table provides information about the project.

 Partnership

Take a look of project's partnership.

Map

 Project objective

The occurrence of cross-border illicit trade and seizures of counterfeit goods by EU-authorities continues to rise year on year. The OECD and the EU’s Intellectual Property Office (EUIPO) estimate that imports of counterfeit and pirated goods are worth nearly half a trillion dollars a year, or around 2.5% of global imports, with US, Italian and French brands the hardest hit. In the EU, the Falsified Medicines Directive (FMD) requires the introduction of a full tracking and tracing system by February 2019. Medicine packs will need to contain a unique identifier (2D barcode) and an anti-tampering device (such as labels), i.e. a technical means to ensure that the content of the package has not been tampered with. At present, there is no technology available on the global market which allows a true authentication of pharmaceutical products themselves, all initiatives so far concentrate on packaging only. SRAP technology overcomes this gap. SRAP is compatible with future FMD regulations; and can provide for fast, reliable and full tracking-and-tracing along the supply chain without the need to destroy product during authentication, while enabling true authentication on the product level - not just the package; and if necessary SRAP solutions provide for a database-independent authentication in the field (via mobile phone) – a very strong set of functionalities that combine to an extremely strong USP. The objectives of feasibility study are as follows – identify 3 potential commercial partners from pharmaceutical industry, define full-scale terms of reference jointly with the 3 partners identified and prepare a full business plan for a new joint venture entity.